naphthalimides has been researched along with Lymphoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borad, MJ; Chalasani, P; Kurtin, S; Mahadevan, D; Northfelt, DW; Rensvold, D; Tibes, R; Von Hoff, DD | 1 |
| Berezin, F; Janisch, L; Lane, LB; Mick, R; Ratain, MJ; Schilsky, RL; Vogelzang, NJ | 1 |
2 trial(s) available for naphthalimides and Lymphoma
| Article | Year |
|---|---|
Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Dogs; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lymphoma; Male; Maximum Tolerated Dose; Mice; Middle Aged; Naphthalimides; Neoplasm Metastasis; Neoplasm Staging; Rats; Urea | 2013 |
Phase I study of amonafide dosing based on acetylator phenotype.
Topics: Acetylation; Adenine; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Imides; Intercalating Agents; Isoquinolines; Lymphoma; Male; Middle Aged; Models, Biological; Naphthalimides; Neoplasms; Organophosphonates; Phenotype | 1993 |